Medicaid Drug Rebate Program Webinar on 9/2 to Provide Critical Updates to Medicaid Rx Professionals

Birmingham, AL, August 27, 2015 --(PR.com)-- Mostly Medicaid runs an industry-leading series of free webinars for the Medicaid industry. The next one is September 2nd and will focus on the Medicaid Drug Rebate Program. Planned topics include AMP rule updates, 340B guidance updates, MDRP data sets, Dispute resolution report from OIG, MDRP underpaying in the news, State Profile: P&T committee efforts in 1 state last 6 months, and MDRP and specialty drugs in the post-Sovaldi era.

Mostly Medicaid webinars draw hundreds of professionals from the Medicaid industry and are available for free. You can check out the upcoming calendar and register by visiting the webinars calendar at mostlymedicaid[dot]com.

MostlyMedicaid.com provides consulting and training services for both public and private sector clients in the Medicaid industry. The Mostly Medicaid publishing audience includes 10,000 Medicaid industry professionals, decision makers and influencers. Mostly Medicaid offers a unique value in the Medicaid industry by focusing on data-driven business perspectives rather than policy-only or advocacy-only positions. Mostly Medicaid was one of the first organizations to actually use the term "Medicaid industry."

Company History
We began with one simple concept in mind - think of Medicaid as a massive industry. Besides the healthcare services provided to Medicaid enrollees, there are hundreds of thousands of people that process claims, build software, consult with hospitals - just to name a few segments.

Those people need services and products to help them do their jobs, increase their revenues and improve their skills.

And that's where Mostly Medicaid comes in.

Because most publishers in the Medicaid industry don't treat the industry like a business - and we do - we are uniquely positioned to reach your customers. We have built a brand those professionals trust to bring actionable counsel and advice to their business challenges.